COMPARISON OF THE CLINICAL AND ECONOMIC IMPACT OF TWO COVID-19 VACCINES IN IMMUNOCOMPROMISED PATIENTS IN FRANCE

被引：0
|
作者：
Uhart, M. [1 ]
Cheret, A. [1 ]
Van de Velde, N. [1 ]
Lee, A. [2 ]
Kohli, M. [2 ]
机构：
[1] Moderna Inc, Cambridge, MA USA
[2] Quadrant Hlth Econ Inc, Cambridge, ON, Canada
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE594
引用
收藏
页码：S167 / S167
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF THE CLINICAL AND ECONOMIC IMPACT OF TWO MRNA COVID-19 VACCINES IN HIGH RISK INDIVIDUALS IN JAPAN
    Kohli, M.
    Hagiwara, Y.
    Igarashi, A.
    Joshi, K.
    Lee, A.
    Maschio, M.
    Van de Velde, N.
    Beck, E.
    VALUE IN HEALTH, 2023, 26 (12) : S77 - S77
  • [2] Vaccines and therapeutics for immunocompromised patients with COVID-19
    Shoham, Shmuel
    Batista, Carolina
    Ben Amor, Yanis
    Ergonul, Onder
    Hassanain, Mazen
    Hotez, Peter
    Kang, Gagandeep
    Kim, Jerome H.
    Lall, Bhavna
    Larson, Heidi J.
    Naniche, Denise
    Sheahan, Timothy
    Strub-Wourgaft, Nathalie
    Sow, Samba O.
    Wilder-Smith, Annelies
    Yadav, Prashant
    Bottazzi, Maria Elena
    ECLINICALMEDICINE, 2023, 59
  • [3] Administration of COVID-19 vaccines in immunocompromised patients
    Negahdaripour, Manica
    Shafiekhani, Mojtaba
    Moezzi, Seyed Mohammad Iman
    Amiri, Sogand
    Rasekh, Shiva
    Bagheri, Ashkan
    Mosaddeghi, Pouria
    Vazin, Afsaneh
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [4] Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
    Lee, Amy
    Davido, Benjamin
    Beck, Ekkehard
    Demont, Clarisse
    Joshi, Keya
    Kohli, Michele
    Maschio, Michael
    Uhart, Mathieu
    El Mouaddin, Nadia
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [5] COMPARISON OF THE CLINICAL AND ECONOMIC IMPACT OF TWO COVID-19 MRNA VACCINES IN HIGH RISK INDIVIDUALS IN THE TOKYO PREFECTURE
    Kohli, M.
    Hagiwara, Y.
    Igarashi, A.
    Joshi, K.
    Lee, A.
    Maschio, M.
    van de Velde, N.
    Beck, E.
    VALUE IN HEALTH, 2023, 26 (12) : S106 - S106
  • [6] Impact of COVID-19 on Pediatric Immunocompromised Patients
    Connelly, James A.
    Chong, Hey
    Esbenshade, Adam J.
    Frame, David
    Failing, Christopher
    Secord, Elizabeth
    Walkovich, Kelly
    PEDIATRIC CLINICS OF NORTH AMERICA, 2021, 68 (05) : 1029 - 1054
  • [7] Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
    Destras, Gregory
    Assaad, Souad
    Bal, Antonin
    Bouscambert-Duchamp, Maude
    Avrillon, Virginie
    Simon, Bruno
    Valette, Martine
    Blay, Jean-Yves
    Lina, Bruno
    Frobert, Emilie
    Josset, Laurence
    LANCET MICROBE, 2021, 2 (09): : 424 - 424
  • [8] COVID-19 vaccination: large impact on reporting of ADRs not related to COVID-19 vaccines in France
    Reactions Weekly, 2023, 1983 (1) : 9 - 9
  • [9] Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
    Galmiche, Simon
    Nguyen, Liem Binh Luong
    Tartour, Eric
    de Lamballerie, Xavier
    Wittkop, Linda
    Loubet, Paul
    Launay, Odile
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (02) : 163 - 177
  • [10] Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients
    Kotton, Camille N.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (06) : 892 - +
12345